8.3.2023 17:18:26 CET | Demant A/S |
Forløb af generalforsamling
Selskabsmeddelelse nr. 2023-04
8. marts 2023
Beslutninger på den ordinære generalforsamling
Demant A/S har i dag afholdt ordinær generalforsamling, der blev afholdt fysisk på selskabets adresse, Kongebakken 9, 2765 Smørum.
I sin tale på generalforsamlingen redegjorde bestyrelsens formand, Niels B. Christiansen, for koncernens udvikling i 2022. Beretningen er tilgængelig på www.demant.com. I sin tale sagde formanden blandt andet:
“Vi kan se tilbage på et år, hvor vi endnu en gang har hjulpet utroligt mange mennesker ved at behandle deres høretab. Vi taler om at have medvirket til screening og diagnosticering af mere end 200 millioner mennesker med et formodet høretab og bidraget til mere end 12 millioner leveår med forbedret livskvalitet. Det er store tal, som også underbygger værdien af vores produkter og services.
Samlet gjorde vi det godt i 2022 i et svært høreapparatmarked. Vores områder Diagnostics og Hearing Aids, har vundet markedsandele. Desværre havde de svære vilkår en negativ effekt på vores samlede resultat, og som følge af en svagere end forventet indtjening sidst på året gennemførte vi omkostningsreducerende tiltag for at tilpasse forretningen til den aktuelle udvikling. For året som helhed leverede vi ikke desto mindre en organisk vækst på 4 %, hvilket vi anser som et solidt resultat under svære betingelser og som et bevis på den styrke, der ligger i vores organisation, kultur og medarbejdere.”
Alle bestyrelsens forslag blev vedtaget af generalforsamlingen. Dette medførte blandt andet følgende beslutninger:
At selskabets årsrapport for 2022 blev godkendt, og at hele årets overskud, DKK 1.439 mio., overføres til selskabets reserver.
At vederlagsrapporten for 2022 blev godkendt.
At den foreslåede forhøjelse af bestyrelseshonoraret blev vedtaget.
At Niels B. Christiansen, Niels Jacobsen, Anja Madsen, Sisse Fjelsted Rasmussen og Kristian Villumsen blev genvalgt som bestyrelsesmedlemmer.
At selskabets revisionsfirma PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC), blev genvalgt.
At selskabets aktiekapital nedsættes med nominelt DKK 1.287.859,00 svarende til selskabets beholdning af egne aktier pr. 15. januar 2023. Beholdningen af egne aktier er erhvervet som led i selskabets aktietilbagekøb i 2022. Som konsekvens af kapitalnedsættelsen ændres vedtægternes pkt. 4.1 senest fire uger efter udløbet af fristen for kreditorers anmeldelse af krav, således at det herefter af pkt. 4.1 vil fremgå, at selskabets aktiekapital udgør DKK 44.787.888,00.
At bestyrelsen blev bemyndiget til indtil næste ordinære generalforsamling at lade selskabet tilbagekøbe aktier med en pålydende værdi af indtil 10 % af aktiekapitalen.
Efter generalforsamlingen konstituerede bestyrelsen sig med Niels B. Christiansen som formand og Niels Jacobsen som næstformand. Sisse Fjelsted Rasmussen fortsætter som formand for revisionsudvalget.
Der har været afholdt valg af medarbejderrepræsentanter til bestyrelsen blandt selskabets medarbejdere. Casper Jensen blev genvalgt, og Charlotte Hedegaard og Heidir Hørby blev nyvalgt – alle blev valgt for en fireårig periode til tiltrædelse efter generalforsamlingen.
I henhold til paragraf 3.8.1 i Nasdaqs Nordic Main Market Rulebook for Issuers of Shares skal Demant hermed give følgende oplysninger som opfølgning på det aktiebaserede program for direktionen, der er en del af direktionens vederlag:
Beskrivelse af programmet
Et langsigtet incitamentsprogram i form af Restricted Stock Units (RSU’er), som efter optjening konverteres 1:1 til aktier i selskabet. Der henvises til selskabets vederlagspolitik for en detaljeret beskrivelse af programmet.
Optjeningsperiode
2023-2026, dvs. tre år
Performance-periode
2023, dvs. et år (det første år af optjeningsperioden)
Aktiekurs
DKK 221,00, dvs. gennemsnittet af kurserne noteret på Nasdaq i København de første fem handelsdage efter offentliggørelse af Demants årsrapport for 2022.
Samlet antal tildelte RSU’er
95.318
Programmets teoretiske markedsværdi
DKK 21.065.278 baseret på den aktiekurs, der anvendes til beregning af tildelingen. Beløbet repræsenterer den maksimale udbetaling, som justeres i forhold til performance-kriterierne.
Yderligere information:
Søren Nielsen, koncernchef og adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Mathias Holten Møller, Head of Investor Relations
Peter Pudselykke, Investor Relations Officer
Trine Kromann-Mikkelsen, VP Corporate Communications and Sustainability
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Vedhæftninger
2023-04 Beslutninger på den ordinære generalforsamling.pdf
8.3.2023 17:18:26 CET | Demant A/S |
Decisions of general meeting
Company announcement no 2023-04
8 March 2023
Decisions of annual general meeting
Today, Demant A/S held its annual general meeting, which took place at the company’s premises, Kongebakken 9, 2765 Smørum.
In his address, the Chair of the Board, Niels B. Christiansen, gave an account of the Group’s development in 2022. The report is available on www.demant.com. He said among other things:
“We can look back on a year where we have once again helped a lot of people by providing treatment to alleviate their hearing loss. We have been instrumental in screening and diagnosing more than 200 million people with a presumed hearing loss and contributed to more than 12 million life years with improved quality of life. These are huge numbers, which also emphasise the value of our products and services.
Overall, we did well in 2022 in a difficult hearing aid market. Our Diagnostics and Hearing Aids business areas have won market shares. Unfortunately, the difficult conditions had a negative impact on our overall results, and because of lower-than-expected profit at the end of the year, we implemented cost reduction initiatives to adjust the business to the current development. For the year as a whole, we nonetheless generated organic growth of 4%, which we consider a solid growth rate under difficult conditions and a testament to the strength of our organisation, culture and employees.”
All proposals put forward by the Board of Directors were adopted by the general meeting, implying among others the following decisions:
The company’s Annual Report 2022 was approved, and the year’s profit, DKK 1,439 million, will be transferred to the company’s reserves.
The Remuneration Report for 2022 was approved.
The proposed raise of the Director’s fee was approved.
Niels B. Christiansen, Niels Jacobsen, Anja Madsen, Sisse Fjelsted Rasmussen and Kristian Villumsen were re-elected to the Board of Directors.
The company’s auditors, PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC), was re-elected.
The company’s share capital will be reduced by nominally DKK 1,287,859.00, corresponding to the company’s holding of treasury shares at 15 January 2023. The company’s holding of treasury shares was acquired during 2022 as part of the company’s share buy-back scheme. As a result of the capital reduction, article 4.1 of the Articles of Association will be amended no later than four weeks after expiry of the deadline for the filing of claims by creditors, which means that upon expiry of this deadline, it will appear from article 4.1 that the company’s share capital is DKK 44,787,888.00.
Until the next ordinary general meeting, the Board was authorised to let the company buy back shares with a nominal value of up to 10% of the share capital.
After the general meeting, the Board of Directors elected Niels B. Christiansen Chair and Niels Jacobsen Vice Chair of the Board. Sisse Fjelsted Rasmussen continues as chair of the audit committee.
An election has been held to find new staff-elected members to the Board of Directors. Casper Jensen was re-elected, and Charlotte Hedegaard and Heidir Hørby were elected new members of the Board of Directors – all for a term of four years starting after the general meeting.
Pursuant to rule 3.8.1 in Nasdaq’s Nordic Main Market Rulebook for Issuers of Shares, Demant hereby provides the following information as follow-up on the share-based programme for the Executive Board, which is part of the Executive Board’s remuneration:
Description of the programme
A long-term incentive programme in the form of restricted stock units (RSUs), which will be converted into shares in the company on a 1:1 ratio at vesting. Please refer to the Remuneration Policy for a detailed description of the programme.
Vesting period
2023-2026, i.e. three years
Performance period
2023, i.e. one year (the first year of the vesting period)
Share price used for grant calculation
DKK 221,00, i.e. the average share price quoted on Nasdaq Copenhagen of the first five trading days following the publication of Demant’s Annual Report 2022.
Total number of RSUs granted
95,318
Theoretical market value of the programme
DKK 21,065,278 based on the share price used for grant calculation and representing the maximum payout to be adjusted based on performance criteria.
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Mathias Holten Møller, Head of Investor Relations
Peter Pudselykke, Investor Relations Officer
Trine Kromann-Mikkelsen, VP Corporate Communications and Sustainability
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Attachments
2023-04 Decisions of annual general meeting.pdf
